In short
Clinical trials are investigating 3-AMINO-4-[2-[[METHYL((111C)METHYL)AMINO]METHYL]PHENYL]SULFANYLBENZONITRILE in brain imaging studies. These trials aim to measure serotonin-related brain changes in people with anorexia nervosa and in people at risk for Parkinson’s disease. They focus on how the brain handles food avoidance and early disease changes.
Key points
- Clinical trials of 3-AMINO-4-[2-[[METHYL((111C)METHYL)AMINO]METHYL]PHENYL]SULFANYLBENZONITRILE are studying brain imaging in two main groups: people with anorexia nervosa and people in the early, prodromal phase of Parkinson’s disease. One trial is Phase 3 and the other is Phase 4. The studies use PET imaging to measure serotonin-related signals in the brain. The anorexia nervosa trial compares patients with control subjects, while the Parkinson’s study compares people with SNCA mutations to healthy controls. The main outcomes focus on binding potential values that help show how the tracer behaves in the brain.
Trial overview
The available trials of 3-AMINO-4-[2-[[METHYL((111C)METHYL)AMINO]METHYL]PHENYL]SULFANYLBENZONITRILE are imaging studies that explore serotonin-related brain activity in specific patient groups.12
These studies are not testing treatment for symptoms; instead, they are using PET imaging to compare brain signals between patient groups and control groups.12
Anorexia nervosa study
The first trial, NCT05155280, is a Phase 3 interventional study in people with anorexia nervosa and control subjects.1
Its goal is to evaluate differences in serotonergic transmission, which means how the serotonin system works in the brain, especially in networks involved in food intake and the striatum, a brain area that helps control behavior and movement.1
The study title also shows that it looks at gaze control and multimodal brain imaging, which means it uses more than one imaging method to study brain function.1
The main outcome is BPND, or non-displaceable binding potential, which is a PET scan measure of how strongly the tracer binds in the brain.1
This trial enrolled 75 participants and is listed as completed.1
Prodromal Parkinson’s disease study
The second trial, 2024-516610-38-00, is a Phase 4 interventional study called SerIAL-PD.2
It studies people with prodromal Parkinson’s disease, which means the early phase before clear Parkinson’s symptoms appear, and it focuses on people with SNCA gene mutations.2
The study compares participants with SNCA mutations who do not yet have Parkinson’s disease to healthy controls without the mutation.2
The trial uses the radiotracers [11C]DASB and [11C]SB207145 to measure binding to the serotonin transporter SERT and the 5-HT4 receptor, both of which are parts of the serotonin system.2
The primary outcome is to determine PET-binding potential and compare it between the study groups.2
This trial plans to enroll 50 participants and is listed as authorised.2
Main outcomes and what they mean
Both trials use PET imaging, which is a scan that shows where a tracer goes in the body and how much it binds to its target.12
In the anorexia nervosa study, the outcome is BPND, while in the Parkinson’s study, the outcome is PET-binding potential for the tracers [11C]DASB and [11C]SB207145.12
These measures help researchers see whether serotonin-related brain signals are different in patients compared with control groups.12
Who can participate
Participation is limited to the groups named in the trial records.12
- The anorexia nervosa study includes people with anorexia nervosa and control subjects.1
- The Parkinson’s study includes people with SNCA mutations who do not yet have Parkinson’s disease, as well as healthy controls.2
Study phases and status
The anorexia nervosa trial is Phase 3 and has been completed.1
The Parkinson’s study is Phase 4 and is authorised.2
Both studies are interventional, meaning the research team gives the study tracer as part of the protocol and measures the brain imaging results.12